Arcturus Therapeutics’ (ARCT) “Buy” Rating Reaffirmed at HC Wainwright
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $63.00 price target on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 249.03% from the stock’s previous close. ARCT has been […]
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $63.00 price target on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 249.03% from the stock’s previous close. ARCT has been […]
